Literature DB >> 17321324

On the genesis and prognosis of variant translocations in chronic myeloid leukemia.

Madhavi Gorusu1, Peter Benn, Zihai Li, Min Fang.   

Abstract

Variant translocations involving 9q, 22q, and at least one additional genomic locus occur in 5-10% of patients with chronic myeloid leukemia (CML). The mechanisms for the formation of these variant translocations are not fully characterized. Studies on the prognosis of these variant translocations revealed conflicting results. In addition, deletions in the derivative chromosome 9 are reportedly more frequent among variant translocation cases. We analyzed cytogenetic and FISH data from 22 CML patients with variant translocations tested at our laboratory. Deletions were observed in 6 of the 14 cases with FISH data available (43%), consistent with the literature and higher than in typical translocation cases (12-15%). Sequential changes of 9q deletions are possible and could be acquired as the disease progresses in addition to simultaneous formation of the Philadelphia chromosome with the deletion. Variant translocation CML patients with a deletion showed a worse cytogenetic response 1 year after therapy than those without a deletion (P < 0.05). Variant translocations may be formed by either a one-step or a two-step mechanism. Proper assessment of the prognostic significance of variant translocations requires better categorization of these translocations based on their mechanisms of genesis and the deletion status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17321324     DOI: 10.1016/j.cancergencyto.2006.10.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  22 in total

1.  Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.

Authors:  Ayda Bennour; Hatem Bellâaj; Yosra Ben Youssef; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-08       Impact factor: 4.553

2.  Conventional and molecular cytogenetic studies to characterize 32 complex variant Philadelphia translocations in patients with chronic myeloid leukemia.

Authors:  Dolors Costa; Javier Grau; Blanca Espinet; Amparo Arias; Cándida Gómez; Mónica López-Guerra; Meritxell Nomdedeu; Francisco Cervantes
Journal:  Oncol Lett       Date:  2019-04-12       Impact factor: 2.967

3.  Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis.

Authors:  Zhenya Tang; Gokce A Toruner; Guilin Tang; C Cameron Yin; Wei Wang; Shimin Hu; Beenu Thakral; Sa A Wang; Roberto N Miranda; Joseph D Khoury; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

Review 4.  Molecular monitoring of chronic myeloid leukemia: present and future.

Authors:  Cecilia Ching Sze Yeung; Daniel Egan; Jerald P Radich
Journal:  Expert Rev Mol Diagn       Date:  2016-09-06       Impact factor: 5.225

5.  Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.

Authors:  Ayda Bennour; Ines Ouahchi; Yosra Ben Youssef; Monia Zaier; Mohamed Adnéne Laatiri; Imed Harrabi; Balkis Meddeb; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2011-04-03       Impact factor: 3.064

6.  Novel four-way Ph translocation t(9;22;7;1)(q34;q11;q22;p13) in a chronic myeloid leukemia patient receiving tyrosine kinase inhibitor therapy.

Authors:  Zámečníkova Adriana; Soad Al Bahar
Journal:  Int J Hematol       Date:  2012-02-10       Impact factor: 2.490

7.  Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia.

Authors:  Qian Li; Xiao-Ji Lin; Hui Chen; Jian Gong; Zhen Li; Xiang-Nan Chen
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

8.  Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.

Authors:  Francesco Albano; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Paola Casieri; Antonella Russo Rossi; Laura Vicari; Vincenzo Liso; Mariano Rocchi; Giorgina Specchia
Journal:  Mol Cancer       Date:  2010-05-25       Impact factor: 27.401

9.  Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.

Authors:  Carmino Antonio de Souza; Katia Borgia Barbosa Pagnano; Israel Bendit; Monika Conchon; Carla Maria Boquimpani de Moura Freitas; Arthur Moellmann Coelho; Vaneuza Araújo Moreira Funke; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2012

10.  A Rare t(9;22;16)(q34;q11;q24) Translocation in Chronic Myeloid Leukemia for Which Imatinib Mesylate Was Effective: A Case Report.

Authors:  Masahiro Manabe; Yumi Yoshii; Satoru Mukai; Erina Sakamoto; Hiroshi Kanashima; Takeshi Inoue; Hirofumi Teshima
Journal:  Leuk Res Treatment       Date:  2011-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.